Cargando…
Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834217/ https://www.ncbi.nlm.nih.gov/pubmed/36631454 http://dx.doi.org/10.1038/s41408-023-00785-y |
| _version_ | 1784868413359783936 |
|---|---|
| author | Goel, Utkarsh Charalampous, Charalampos Kapoor, Prashant Binder, Moritz Buadi, Francis K. Dingli, David Dispenzieri, Angela Fonder, Amie Gertz, Morie A. Gonsalves, Wilson I. Hayman, Suzanne R. Hobbs, Miriam A. Hwa, Yi L. Kourelis, Taxiarchis Lacy, Martha Q. Leung, Nelson Lin, Yi Warsame, Rahma M. Kyle, Robert A. Rajkumar, S. Vincent Kumar, Shaji K. |
| author_facet | Goel, Utkarsh Charalampous, Charalampos Kapoor, Prashant Binder, Moritz Buadi, Francis K. Dingli, David Dispenzieri, Angela Fonder, Amie Gertz, Morie A. Gonsalves, Wilson I. Hayman, Suzanne R. Hobbs, Miriam A. Hwa, Yi L. Kourelis, Taxiarchis Lacy, Martha Q. Leung, Nelson Lin, Yi Warsame, Rahma M. Kyle, Robert A. Rajkumar, S. Vincent Kumar, Shaji K. |
| author_sort | Goel, Utkarsh |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9834217 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98342172023-01-13 Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma Goel, Utkarsh Charalampous, Charalampos Kapoor, Prashant Binder, Moritz Buadi, Francis K. Dingli, David Dispenzieri, Angela Fonder, Amie Gertz, Morie A. Gonsalves, Wilson I. Hayman, Suzanne R. Hobbs, Miriam A. Hwa, Yi L. Kourelis, Taxiarchis Lacy, Martha Q. Leung, Nelson Lin, Yi Warsame, Rahma M. Kyle, Robert A. Rajkumar, S. Vincent Kumar, Shaji K. Blood Cancer J Correspondence Nature Publishing Group UK 2023-01-11 /pmc/articles/PMC9834217/ /pubmed/36631454 http://dx.doi.org/10.1038/s41408-023-00785-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence Goel, Utkarsh Charalampous, Charalampos Kapoor, Prashant Binder, Moritz Buadi, Francis K. Dingli, David Dispenzieri, Angela Fonder, Amie Gertz, Morie A. Gonsalves, Wilson I. Hayman, Suzanne R. Hobbs, Miriam A. Hwa, Yi L. Kourelis, Taxiarchis Lacy, Martha Q. Leung, Nelson Lin, Yi Warsame, Rahma M. Kyle, Robert A. Rajkumar, S. Vincent Kumar, Shaji K. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma |
| title | Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma |
| title_full | Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma |
| title_fullStr | Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma |
| title_full_unstemmed | Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma |
| title_short | Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma |
| title_sort | defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834217/ https://www.ncbi.nlm.nih.gov/pubmed/36631454 http://dx.doi.org/10.1038/s41408-023-00785-y |
| work_keys_str_mv | AT goelutkarsh definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma AT charalampouscharalampos definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma AT kapoorprashant definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma AT bindermoritz definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma AT buadifrancisk definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma AT dinglidavid definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma AT dispenzieriangela definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma AT fonderamie definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma AT gertzmoriea definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma AT gonsalveswilsoni definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma AT haymansuzanner definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma AT hobbsmiriama definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma AT hwayil definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma AT kourelistaxiarchis definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma AT lacymarthaq definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma AT leungnelson definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma AT linyi definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma AT warsamerahmam definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma AT kyleroberta definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma AT rajkumarsvincent definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma AT kumarshajik definingdrugdrugclassrefractorinessvslinesoftherapyinrelapsedrefractorymultiplemyeloma |